A public health campaign developed by McCann Health India for children in Afghanistan was the big winner in 2017.
The jury said the year's best work in the category was a public-health campaign.
In the Lions Health pharma shortlist, released Saturday morning, five branded campaign made it through the judging process for the branded prescription categories.
Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO
Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research
The association also recommended that the Centers for Medicare and Medicaid Services negotiate drug prices.
The FDA-approved app will allow MS patients to share their medication injection history with HCPs.
Consent forms and reimbursement are the main deterrents of offering the service.
Sanofi to boost investment in biologics R&D; Sage's awareness campaign criticized; PatientsLikeMe poll finds 95% of patients want some costs of drugs covered
Alkermes lobbies lawmakers on its opioid addiction drug; rep salaries rise; SCOTUS rules in favor of Sandoz in biosimilar suit
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
It's never been easy for pharmaceutical companies or healthcare brands to authentically engage with patients or with doctors.
The CEO of FCB Health shares her gelato secrets and talks about why this year is truly the year of healthcare.
He buys macarons to make friends and finds that Cannes is an "extraordinary opportunity to rewire your brain."
Words of the wise: Vacant the Gutter Bar by 2 a.m., and make sure to bring flip flops and go walk on the beach.
The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.
The FDA asks Endo to take opioid off the market; Lilly partners with Swiss biotech; House committee advances PDUFA bill — without off-label provision
Executives discussed the challenges and opportunities they have faced as women.
Novartis CAR-T drug boasts competitive response rates; WPP reports slowing sales for healthcare business; AZ sells migraine drug
The opportunity to reach the millennial audience is great, and there's a lot that brands can do now to ensure that companies stay relevant to Gen Y cultural trends.
Pfizer receives breakthrough designation for experimental rare disease drug; Endocyte cuts 30 jobs; AbbVie RA drug meets Phase-III goals
The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.
The genetics testing company helps Gru find his lost-lost brother in six-week marketing push.
With physicians spending nearly four hours a day on their electronic health records, experts say voice assistants could help reduce their workload one day.
Pfizer increased drug prices by 20% in 2017; Perrigo CEO to retire; MannKind sponsors reality TV show to promote Afrezza
They are asking the American Medical Association to support the policy proposal.
Notably, data for AstraZeneca's Lynparza, Johnson & Johnson's Zytiga, and Loxo Oncology's larotrectinib highlights the move toward specialized medicine.
Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices
Putting aside the hype around combination immunotherapies, concerns remain about overall response rates for these drugs.
The executive director of oncology marketing is fascinated by the resilience of the human body.
Oncologists more likely to prescribe drugs when receiving travel, meal payments; Tesaro reportedly considering a sale; AbbVie has best pharma reputation
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
This includes concerns about the effectiveness — and cost-effectiveness — of drugs like Merck's Keytruda and Bristol-Myers Squibb's Opdivo, in combination or alone.
BMS partners on Opdivo combo; one-quarter of insurers have signed an outcomes-based contract with a drugmaker; rebates do not lead to savings for Medicare beneficiaries
The deal highlights ongoing interest in the influential point-of-care market.
Harvard Pilgrim signs two outcomes contracts with AstraZeneca; lobbyists fight over drug-pricing proposals; docs say no to adult ADHD screening test
The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
The company said adult women between the ages of 50 and 70 are most likely to share content on the social media platform.
Fitness trackers do not reliably track calories, docs find; health-tech startups face market uncertainty; FDA adcom votes in favor of Puma breast-cancer drug
Twitter has launched a customizable Direct Message Card that brands can use to promote and share the bots or other customer experiences they've created, while Snapchat and Instagram have launched stories updates.
Keytruda receives first approval based on a genetic feature and not tumor's location; Alexion reps reportedly crossed ethical lines; profits up at insurers
The regulator also took issue with how Orexigen Therapeutics presented the risk information
This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.
Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.
The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.
Recent grads aren't afraid to voice their expectations, and agencies are responding with new programs and policies.
An FDA advisory committee is expected to decide Wednesday whether to recommend neratinib for approval.
Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug
Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial
Siri and accessibility features take center stage in ads for Global Accessibility Awareness Day.
Keytruda gets two new FDA approvals; lawmakers aim to speed up approval of generics; Incyte uses soap opera to spread rare-disease awareness
In general, physicians believe that information provided by pharma companies is difficult to find and lacking in science.
Docs spend little time telling patients about cancer costs; Shire to file hereditary angioedema drug with the FDA by 2018; Philips CEO on access obstacles
Robert Califf stepped down from his role as FDA commissioner in January.
FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations
The ad-tax deduction is likely once again on the table.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."
Drugmakers and providers alike struggle to find the best tools, words, and technologies that will improve adherence rates among patients with chronic diseases.
Funding for patient-assistance charities makes up 7% of operating expenses for drugmakers; Avanir ad under fire; Trump to consider Medicare rebates
For Mother's Day, the agency gives job-hunters a way to proudly display maternity leave as a full-time job.
AstraZeneca's Imfinzi improves survival in lung cancer in trial; Blue Cross Blue Shield partners with Lyft; Lilly to submit migraine drug to FDA
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
Palmer spent seven years at JUICE and was a managing partner.
The deal will create one of the three biggest contract research organizations in the world.
Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.
The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study
CVS has a pharmacy text program to remind patients to refill their prescriptions and alert them when their medications are ready.
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
The community manager of the smoking-prevention nonprofit reveals the key ways he drives engagement among online community members
In the wake of high-profile brand flops, everyone from clients to creative teams seeks the counsel of experts.
Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions
Amidst the massive technological and social changes upending the societal status quo, the culture of doctors around the globe is also in flux. Technology must be humanized to advance care. McCann Health's "Truth About Doctors" study uncovers what this means for pharma marketers and how the industry can help doctors future-proof their profession.
CVS formulary changes lifted Tresiba sales; Novartis licenses NASH drug; FDA is building digital health unit
Claritin is fighting the "indoor epidemic" with its Be an Outsider campaign
Louisiana may use 1910 law to discount hep-C drugs; House bill would reduce coverage for 24 million people; drugmakers pursue pay-for-performance deals
Holly Henry, previously chief medical officer at FCB Health, will oversee medical strategy in the newly created role.
This is likely due to fewer product launches and lower price increases.
The drugmaker is is using Tumblr, Snapchat, and YouTube as well as gay dating apps like Grindr to promote its HIV prevention pill.
Teaching hospitals that limit detailing prescribe fewer branded drugs; new ad campaign criticizes drug pricing; Ad Age reports healthcare is fastest growing agency discipline
To demonstrate the power of goggles equipped with AR and VR, the assistive technology company recreated the event on Facebook Live this weekend.
Ketchum, which launched a parent specialty unit, surveyed 400 first-time parents to find out what brands are doing well and how they can do better.
Sales of Merck's Keytruda double in the first quarter; the FDA approves AstraZeneca's immunotherapy; Lilly's insulin is under investigation in two states
The artificial pancreas can provide value to the health system.
Execs stressed the importance of collaboration, consumer-mindedness.
One executive referred to AI as a "black box" and as the "Tower of Babel."
In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.
The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.
Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
Sandoz counsel argued that Amgen's position "wrongly delays the marketing of every biosimilar."
Novartis, Kaiser, and Qualcomm partner on heart-failure pilot; Novartis and GSK disclose DTC plans; cancer-treatment hype can be negative for patients
GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products
The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.
Sanofi sues Mylan over anticompetitive practices; Anthem to drop Express Scripts; GSK chief digital officer says advertisers should focus on fewer publishers
The Canadian contact lens etailer partnered with a new technology vendor to look beyond its direct click-to-conversions.
QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1
Josephine Martin was previously EVP of public affairs at PhRMA.